Efficacy of ripasudil-brimonidine fixed-dose combination in secondary glaucoma associated with uveitis: a retrospective study
Year: 2026
Type: article
Study design: Observational Study
Abstract: PURPOSE: To evaluate the intraocular pressure (IOP)-lowering efficacy and treatment stability of ripasudil-brimonidine fixed-dose combination (RBFC) in patients with secondary glaucoma associated with uveitis. STUDY DESIGN: Single-center, retrospective study. METHODS: Medical records of 50 eyes prescribed RBFC were reviewed and categorized into inflammatory ocular hypertension (OH; n = 19), steroid-induced OH (n = 18), and primary open-angle glaucoma (POAG; n = 13). Clinical parameters-including IOP, visual acuity (VA), and medication score-were assessed at baseline, the first follow-up, and the final visit. RESULTS: In the inflammatory and steroid-induced OH groups, mean IOP decreased significantly from baseline and remained stable throughout the observation period (P < 0.001). VA was maintained with a slight, non-significant improvement, and medication scores remained stable, indicating sustained treatment efficacy without additional eye drops. One mild case of conjunctivitis occurred in the POAG group. CONCLUSION: RBFC was associated with significant IOP reduction in eyes with uveitis-associated or steroid-induced OH, without compromising visual function. These findings suggest that RBFC may be a useful therapeutic option for inflammation-related secondary glaucoma.
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,790
Funder: National Defense Medical College
OpenAlex ID: W7155194247